Replies to post #215678 on Biotech Values

[biocqr]

RVNC > re:acquisition.. my bet is on Nestlé...

Health-minded Nestlé recruits Allergan exec to drive big ambitions for skincare unit

https://www.fiercepharma.com/pharma/nestle-taps-allergan-exec-to-lead-growing-skincare-unit

Nestlé said it was serious about taking on its larger rivals in the dermatology field. Now, it’s poaching from one of its competitors to gain a leader for that fight.

Soon after bringing in a pharma veteran to serve as CEO, the food giant tapped an Allergan exec--Paul Navarre, president of Allergan’s international business--to succeed Humberto Antunes as chief of Nestlé Skin Health. Antunes is leaving to pursue a “new direction,” the company said.

Not coincidentally, Nestlé has co-marketing rights to Dysport, a Botox rival, outside the U.S. and Canada, as well as several other injectable cosmetic treatments the Swiss giant bought from Valeant for $1.4 billion in 2014. So, Navarre's skincare and aesthetics experience may be exactly what Nestlé needs to make the most of that portfolio, which includes Restylane, Perlane and Emervel, among others.